Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00810758 · ClinicalTrials.gov registry record · Phase 1
Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691
A Phase 1 study of Hepatitis C Virus, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00810758: Completed Phase 1 study of Hepatitis C Virus, sponsored by Pfizer.
NCT00810758 is a Phase 1 study of Hepatitis C Virus that has completed, run by Pfizer. The registered enrollment target is 24 participants, below the 310-participant average among 3 other Hepatitis C Virus trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00810758, a Phase 1 study of Hepatitis C Virus, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of PF-04878691.
Conditions Studied
Interventions
- DRUG PF-04878691 3mg
- DRUG PF-04878691 6mg
- DRUG PF-04878691 9mg
Study Locations (1)
Connecticut
- Pfizer Investigational Site - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-11 |
| Phase | Phase 1 |
What the finished NCT00810758 record still lists
NCT00810758 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 310-participant average among 3 other Hepatitis C Virus trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Hepatitis C Virus appearing as the primary indexed condition, and to 3 interventions - of which PF-04878691 3mg is the first listed.
NCT00810758 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00810758 about?
NCT00810758 is a clinical study titled "Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691". To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of PF-04878691.
What is the current status of trial NCT00810758?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2009-01. Estimated completion is 2009-11.
What conditions does trial NCT00810758 study?
This clinical trial studies the following conditions: Hepatitis C Virus.
What interventions are being tested in trial NCT00810758?
The interventions under investigation include: PF-04878691 3mg (DRUG), PF-04878691 6mg (DRUG), PF-04878691 9mg (DRUG).
Who is sponsoring clinical trial NCT00810758?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00810758 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening
RECRUITING · NA
-
Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment
COMPLETED · Phase 2
-
Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia